Core Viewpoint - Zhonghong Medical is expected to report a net profit loss of 125 million to 186 million yuan for the entire year of 2025, primarily due to industry cycles, price fluctuations, and currency exchange rate impacts [1] Group 1: Performance Forecast - The company attributes the expected performance decline to several factors, including the cyclical nature and price volatility of the protective glove industry, as well as the appreciation of the RMB against the USD [1] - The company plans to recognize impairment provisions for fixed assets and inventory totaling approximately 27 million to 41 million yuan due to signs of impairment [1] - An initial assessment of goodwill related to the acquisition of Guilin Hengbao Health Protection Co., Ltd. indicates potential impairment, with expected provisions of about 58 million to 88 million yuan [1] - Non-recurring gains and losses are expected to impact the net profit attributable to shareholders by approximately 38 million to 75 million yuan, mainly from investment income and government subsidies [1] Group 2: Q3 Financial Results - For the first three quarters of 2025, the company's main revenue reached 1.864 billion yuan, a year-on-year increase of 1.38% [2] - The net profit attributable to shareholders was -7.21 million yuan, a year-on-year decrease of 114.13% [2] - The non-recurring net profit was -37.34 million yuan, a significant year-on-year decline of 20,229.69% [2] - In Q3 2025, the company's single-quarter main revenue was 626 million yuan, a year-on-year decrease of 9.24% [2] - The single-quarter net profit attributable to shareholders was -12.95 million yuan, a year-on-year decrease of 170.01% [2] - The single-quarter non-recurring net profit was -24.17 million yuan, a year-on-year decline of 691.19% [2] - The company's debt ratio stood at 28.02%, with investment income of 8.76 million yuan and financial expenses of -17.67 million yuan, while the gross profit margin was 10.54% [2]

Core Viewpoint - Zhonghong Medical is expected to report a net profit loss of between 87 million to 130 million yuan for the full year of 2025 due to various factors impacting its performance [1] Group 1: Performance Forecast - The company attributes the expected performance decline to industry cycle and price fluctuations in the protective glove sector, as well as the appreciation of the RMB against the USD [1] - The company plans to recognize impairment provisions for fixed assets and inventory totaling approximately 27 million to 41 million yuan due to signs of impairment [1] - An initial assessment of goodwill related to the acquisition of Guilin Hengbao Health Protection Co., Ltd. indicates potential impairment, with expected provisions of about 58 million to 88 million yuan [1] - Non-recurring gains and losses are anticipated to impact the net profit attributable to shareholders by approximately 38 million to 75 million yuan, mainly from investment income and government subsidies [1] Group 2: Q3 Financial Results - For the first three quarters of 2025, the company's main revenue reached 1.864 billion yuan, a year-on-year increase of 1.38% [2] - The net profit attributable to shareholders was -7.21 million yuan, a year-on-year decrease of 114.13% [2] - The company's net profit after deducting non-recurring items was -37.34 million yuan, a significant year-on-year decline of 20,229.69% [2] - In Q3 2025, the company reported a single-quarter main revenue of 626 million yuan, a year-on-year decrease of 9.24% [2] - The single-quarter net profit attributable to shareholders was -12.95 million yuan, a year-on-year decrease of 170.01% [2] - The single-quarter net profit after deducting non-recurring items was -24.17 million yuan, a year-on-year decline of 691.19% [2] - The company's debt ratio stood at 28.02%, with investment income of 8.76 million yuan and financial expenses of -17.67 million yuan, while the gross profit margin was 10.54% [2]

Core Viewpoint - Zhonghong Medical (300981.SZ) expects a net profit attributable to shareholders of the listed company to be between -130.5 million and -87 million yuan for 2025, compared to -87.13 million yuan in the same period last year [1] Group 1: Financial Performance - The net profit after deducting non-recurring gains and losses is projected to be between -186.5 million and -124.5 million yuan [1] - The company reported a significant impact on its performance due to the cyclical nature and price fluctuations in the protective glove industry, as well as the appreciation of the RMB against the USD [1] Group 2: Asset Impairment - During the reporting period, the company recognized impairment provisions for fixed assets and inventory totaling approximately 27 million to 41 million yuan due to signs of impairment [1] - The final impairment amount will be determined based on the audit data from the accounting firm [1]

Group 1 - The company expects a net profit attributable to shareholders for the year 2025 to be between -130 million and -87 million yuan, with a net profit excluding non-recurring gains and losses projected to be between -186 million and -125 million yuan [1] - The performance of the company is significantly impacted by the cyclical nature and price fluctuations in the protective glove industry, as well as the appreciation of the RMB against the USD [1]

证券代码：300981 证券简称：中红医疗 公告编号：2026-010 中红普林医疗用品股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预告情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 （1）以区间数进行业绩预告 1、报告期内，防护手套类产品行业周期及价格波动，以及人民币对美元升 值等因素对公司业绩产生较大影响。 2、报告期内，公司结合行业发展、市场变化及经营情况，对部分出现减值 迹象的固定资产、存货计提减值准备合计约 0.27 亿元至 0.41 亿元，最终减值金 额以会计师事务所审计数据为准。 3、本报告期末，公司聘请的评估机构，对公司收购桂林恒保健康防护有限 公司（以下简称"恒保健康"）所形成的商誉进行了初步评估和测算。结合行业 发展、市场变化和实际经营情况等因素，判断恒保健康所形成的商誉出现减值迹 象。为更加客观、公正地反映公司的财务状况和资产价值，根据《企业会计准则 第 8 号-资产减值》等相关会计政策规定，按照谨慎性原则 ...

联系电话：0315-4155760 证券代码：300981 证券简称：中红医疗 公告编号：2026-009 中红普林医疗用品股份有限公司 关于公司董事会秘书取得任职培训证明并正式履职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）于 2025 年 11 月 17 日召开第四届董事会第十四次会议，审议通过了《关于聘任董事会秘书的议案》， 经公司薪酬考核与提名委员会审查通过后，同意聘任邓伟先生为公司第四届董事 会的董事会秘书，上述任期自本次董事会审议通过之日起至第四届董事会任期结 束之日止。鉴于聘任时，邓伟先生尚未取得深圳证券交易所认可的董事会秘书资 格证书，董事会指定其代行董事会秘书职责，待其取得相关资格证明后，正式履 行董事会秘书职责。具体内容详见 2025 年 11 月 17 日公司在巨潮资讯网 （www.cninfo.com.cn）披露的《关于董事会秘书辞职及聘任董事会秘书的公告》 （公告编号：2025-101）。 近日，邓伟先生已取得了深圳证券交易所颁发的上市公司董事会秘书培训证 明，根据公司第四届 ...

Investment Rating - The report maintains an "Outperform" rating for the medical and biotechnology industry [1]. Core Insights - The global demand for disposable gloves has recovered to pre-pandemic levels and is expected to grow steadily, with a projected compound annual growth rate (CAGR) of approximately 10% from 2022 to 2025, reaching a sales revenue of $13.6 billion by 2025 [3][11]. - The nitrile glove segment is anticipated to see significant growth, with the global medical nitrile glove market expected to reach $7.86 billion in 2024 and $16.31 billion by 2031, reflecting a CAGR of 11.2% from 2025 to 2031 [3][28]. - The industry is transitioning towards a balanced supply-demand scenario, with a gradual recovery in prices and profitability expected as high-cost capacities are phased out [4][47]. Summary by Sections Industry Overview - Disposable gloves are primarily used in medical settings, with nitrile gloves emerging as the preferred material due to their superior properties [9][12]. Market Cycle - The industry is expected to return to a phase of volume and price increases after experiencing supply-demand fluctuations, with a notable recovery in nitrile glove demand and pricing anticipated [22][46]. Investment Recommendations - The report suggests focusing on leading companies with advantages in capacity, cost control, and global expansion, such as Yingke Medical, Zhonghong Medical, and Blue Sail Medical [5][59]. Demand Side - The demand for disposable gloves is driven by increasing healthcare spending and heightened awareness of hygiene and protection across various sectors, particularly in developed markets [25][26]. Supply Side - The supply landscape is characterized by a concentration of production in Southeast Asia and China, with domestic leading manufacturers narrowing the capacity gap with Southeast Asian competitors [34][42]. Cost and Pricing Dynamics - The production costs of gloves are significantly influenced by raw material prices, particularly nitrile latex, which constitutes about 50% of production costs [50][54]. Price trends are expected to stabilize and potentially increase as demand recovers and high-cost production capacities exit the market [57][61].

Group 1 - The Hebei Securities Regulatory Bureau emphasizes the importance of regular visits to listed companies as a means to enhance regulatory effectiveness and support high-quality development in the capital market [1][2] - A comprehensive visit mechanism has been established, ensuring that all listed companies in the region are visited, which helps in accurately understanding their operational status and addressing practical issues [2][4] - The bureau has created a collaborative visiting mechanism involving various departments and institutions to effectively address the complex demands and challenges faced by listed companies [2][3] Group 2 - The bureau has focused on key industries and specific companies, such as Zhongci Electronics and Yiling Pharmaceutical, to understand their development needs and assist in strategic growth [4] - In 2025, 64 listed companies in the region implemented cash dividends totaling 24.652 billion yuan, marking a 14.70% increase year-on-year, indicating a rising level of shareholder returns [5] - The bureau has introduced an integrated work mechanism that combines inspections with visits, enhancing regulatory precision while minimizing disruptions to normal business operations [7] Group 3 - The bureau plans to continue refining its regular visit mechanism, tracking the progress of issues raised by companies and optimizing service delivery through various initiatives [8] - Training programs have been conducted to improve governance and operational standards among listed companies, with nearly 3,000 participants involved [7] - The establishment of a dynamic tracking system for company issues ensures that all concerns are addressed systematically, with clear accountability and follow-up [7]

Core Viewpoint - 中红医疗 plans to engage in low-risk financial investments and hedging activities in 2026 to enhance financial stability and mitigate risks associated with currency and commodity price fluctuations [1][2][3][5] Group 1: Financial Activities - 中红医疗 intends to use up to 2 billion RMB of idle funds to invest in low-risk financial products with a maximum investment period of 36 months [5] - The company plans to conduct foreign exchange derivative transactions with a maximum balance of 500 million USD to manage currency risk, using its own funds [2][3][4] - The company aims to engage in commodity futures hedging with a total transaction amount not exceeding 50 million RMB, also funded by its own resources [2][3] Group 2: Governance and Approval - The board of 中红医疗 approved several proposals on January 19, 2026, which will be submitted for shareholder approval at the first extraordinary general meeting on February 5, 2026 [1][5] - The proposals include the use of idle funds for low-risk investments, foreign exchange derivative transactions, and commodity futures hedging, with related party transactions requiring abstention from voting by related shareholders [1][2]

Trading Information - As of January 19, 2026, Zhonghong Medical (300981) closed at 13.39 yuan, up 0.75%, with a turnover rate of 0.89% and a trading volume of 34,900 shares, amounting to 46.4462 million yuan [1] - On January 19, 2026, the net outflow of main funds was 2.9472 million yuan, while retail investors saw a net inflow of 0.9156 million yuan [1] Company Announcements - Zhonghong Medical announced it will provide a guarantee of 50 million yuan for its wholly-owned subsidiary, Zhonghong International (Hong Kong) Trading Co., Ltd., in a financing contract with China Construction Bank [1] - The guarantee period is three years from the maturity of the main debt, and the subsidiary's latest asset-liability ratio is 94% [1] - The total guarantee amount for the company and its subsidiaries is 735 million yuan, accounting for 13.43% of the latest audited net assets, with no overdue guarantees [1] Board Meeting Resolutions - On January 19, 2026, Zhonghong Medical held its 16th meeting of the fourth board of directors, approving several proposals including the use of idle funds for low-risk financial products and foreign exchange derivatives trading [2] - The proposals will be submitted for approval at the first extraordinary shareholders' meeting of 2026, scheduled for February 5, 2026 [2] Financial Management Strategies - The company plans to invest up to 2 billion yuan of idle self-owned funds in low-risk financial products with a maximum investment period of 36 months [5] - The investment will focus on R1 and R2 rated financial products issued by commercial banks, trusts, and other financial institutions [5] - The company aims to conduct commodity futures hedging with a maximum trading margin of 5 million yuan and a total trading amount not exceeding 50 million yuan, using self-owned funds [3][4] Foreign Exchange Derivatives Trading - Zhonghong Medical intends to engage in foreign exchange derivatives trading to mitigate exchange rate risks, with a maximum balance of 500 million USD at any time [3][4] - The trading will include foreign exchange forwards, swaps, and options, with the funds sourced from self-owned capital [4]